Rare disease registries are key to evidence-based personalized medicine: highlighting the european experience

Rare diseases, such as inherited metabolic diseases, have been identified as a health priority within the European Union more than 20 years ago and have become an integral part of EU health programs and European Reference Networks. Having the potential to pool data, to achieve sufficient sample size...

Full description

Saved in:
Bibliographic Details
Main Authors: Kölker, Stefan (Author) , Gleich, Florian (Author) , Mütze, Ulrike (Author) , Opladen, Thomas (Author)
Format: Article (Journal)
Language:English
Published: 04 March 2022
In: Frontiers in endocrinology
Year: 2022, Volume: 13, Pages: 1-11
ISSN:1664-2392
Online Access:Verlag, kostenfrei, Volltext: https://www.frontiersin.org/article/10.3389/fendo.2022.832063
Get full text
Author Notes:Stefan Kölker, Florian Gleich, Ulrike Mütze and Thomas Opladen on behalf of Scientific Consortia of E-IMD, E-HOD, iNTD, U-IMD, and MetabERN

MARC

LEADER 00000caa a2200000 c 4500
001 1801176477
003 DE-627
005 20230427140252.0
007 cr uuu---uuuuu
008 220509s2022 xx |||||o 00| ||eng c
035 |a (DE-627)1801176477 
035 |a (DE-599)KXP1801176477 
035 |a (OCoLC)1341459734 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Kölker, Stefan  |e VerfasserIn  |0 (DE-588)1022937758  |0 (DE-627)717335771  |0 (DE-576)366197568  |4 aut 
245 1 0 |a Rare disease registries are key to evidence-based personalized medicine  |b highlighting the european experience  |c Stefan Kölker, Florian Gleich, Ulrike Mütze and Thomas Opladen on behalf of Scientific Consortia of E-IMD, E-HOD, iNTD, U-IMD, and MetabERN 
264 1 |c 04 March 2022 
300 |a 11 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 31.05.2022 
520 |a Rare diseases, such as inherited metabolic diseases, have been identified as a health priority within the European Union more than 20 years ago and have become an integral part of EU health programs and European Reference Networks. Having the potential to pool data, to achieve sufficient sample size, to overcome the knowledge gap on rare diseases and to foster epidemiological and clinical research, patient registries are recognized as key instruments to evidence-based medicine for individuals with rare diseases. Patient registries can be used for multiple purposes, such as (1) describing the natural history and phenotypic diversity of rare diseases, (2) improving case definition and indication to treat, (3) identifying strategies for risk stratification and early prediction of disease severity (4), evaluating the impact of preventive, diagnostic, and therapeutic strategies on individual health, health economics, and the society, and (5) informing guideline development and policy makers. In contrast to clinical trials, patient registries aim to gather real-world evidence and to achieve generalizable results based on patient cohorts with a broad phenotypic spectrum. In order to develop a consistent and sustained framework for rare disease registries, uniform core principles have been formulated and have been formalized through the European Rare Disease Registration Infrastructure. Adherence to these core principles and compliance with the European general data protection regulations ensures that data collected and stored in patient registries can be exchanged and pooled in a protected environment. To illustrate the benefits and limitations of patient registries on rare disease research this review focuses on inherited metabolic diseases. 
700 1 |a Gleich, Florian  |e VerfasserIn  |0 (DE-588)1114740195  |0 (DE-627)86900445X  |0 (DE-576)47746100X  |4 aut 
700 1 |a Mütze, Ulrike  |d 1979-  |e VerfasserIn  |0 (DE-588)135567963  |0 (DE-627)693593024  |0 (DE-576)279666438  |4 aut 
700 1 |a Opladen, Thomas  |d 1974-  |e VerfasserIn  |0 (DE-588)124489656  |0 (DE-627)642820481  |0 (DE-576)335321291  |4 aut 
773 0 8 |i Enthalten in  |t Frontiers in endocrinology  |d Lausanne : Frontiers Research Foundation, 2010  |g 13(2022), Artikel-ID 832063, Seite 1-11  |h Online-Ressource  |w (DE-627)645090948  |w (DE-600)2592084-4  |w (DE-576)336962975  |x 1664-2392  |7 nnas  |a Rare disease registries are key to evidence-based personalized medicine highlighting the european experience 
773 1 8 |g volume:13  |g year:2022  |g elocationid:832063  |g pages:1-11  |g extent:11  |a Rare disease registries are key to evidence-based personalized medicine highlighting the european experience 
856 4 0 |u https://www.frontiersin.org/article/10.3389/fendo.2022.832063  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20220509 
993 |a Article 
994 |a 2022 
998 |g 124489656  |a Opladen, Thomas  |m 124489656:Opladen, Thomas  |d 910000  |d 910500  |d 50000  |e 910000PO124489656  |e 910500PO124489656  |e 50000PO124489656  |k 0/910000/  |k 1/910000/910500/  |k 0/50000/  |p 4  |y j 
998 |g 135567963  |a Mütze, Ulrike  |m 135567963:Mütze, Ulrike  |d 910000  |d 910500  |d 50000  |e 910000PM135567963  |e 910500PM135567963  |e 50000PM135567963  |k 0/910000/  |k 1/910000/910500/  |k 0/50000/  |p 3 
998 |g 1114740195  |a Gleich, Florian  |m 1114740195:Gleich, Florian  |p 2 
998 |g 1022937758  |a Kölker, Stefan  |m 1022937758:Kölker, Stefan  |d 910000  |d 910500  |d 50000  |e 910000PK1022937758  |e 910500PK1022937758  |e 50000PK1022937758  |k 0/910000/  |k 1/910000/910500/  |k 0/50000/  |p 1  |x j 
999 |a KXP-PPN1801176477  |e 4130256912 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"part":{"year":"2022","volume":"13","pages":"1-11","text":"13(2022), Artikel-ID 832063, Seite 1-11","extent":"11"},"origin":[{"dateIssuedDisp":"2010-","dateIssuedKey":"2010","publisher":"Frontiers Research Foundation","publisherPlace":"Lausanne"}],"id":{"issn":["1664-2392"],"zdb":["2592084-4"],"eki":["645090948"]},"disp":"Rare disease registries are key to evidence-based personalized medicine highlighting the european experienceFrontiers in endocrinology","recId":"645090948","title":[{"title":"Frontiers in endocrinology","title_sort":"Frontiers in endocrinology"}],"pubHistory":["1.2010 -"],"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"titleAlt":[{"title":"Bone Research"},{"title":"Cancer Endocrinology"},{"title":"Cellular Endocrinology"},{"title":"Diabetes"},{"title":"Endocrinology of Aging"},{"title":"Experimental Endocrinology"},{"title":"Genomic Endocrinology"},{"title":"Molecular and Structural Endocrinology"},{"title":"Neuroendocrine Science"},{"title":"Pediatric Endocrinology"},{"title":"Pituitary Endocrinology"},{"title":"Systems and Translational Endocrinology"},{"title":"Thyroid Endocrinology"}],"note":["Gesehen am 12.12.19","Specialty sections: Bone Research; Cancer Endocrinology; Cellular Endocrinology; Diabetes; Endocrinology of Aging; Experimental Endocrinology; Genomic Endocrinology; Molecular and Structural Endocrinology; Neuroendocrine Science; Pediatric Endocrinology; Pituitary Endocrinology; Systems and Translational Endocrinology; Thyroid Endocrinology"],"type":{"bibl":"periodical","media":"Online-Ressource"}}],"note":["Gesehen am 31.05.2022"],"name":{"displayForm":["Stefan Kölker, Florian Gleich, Ulrike Mütze and Thomas Opladen on behalf of Scientific Consortia of E-IMD, E-HOD, iNTD, U-IMD, and MetabERN"]},"recId":"1801176477","id":{"eki":["1801176477"]},"origin":[{"dateIssuedDisp":"04 March 2022","dateIssuedKey":"2022"}],"physDesc":[{"extent":"11 S."}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"display":"Kölker, Stefan","role":"aut","given":"Stefan","family":"Kölker"},{"given":"Florian","role":"aut","family":"Gleich","display":"Gleich, Florian"},{"display":"Mütze, Ulrike","role":"aut","given":"Ulrike","family":"Mütze"},{"given":"Thomas","role":"aut","family":"Opladen","display":"Opladen, Thomas"}],"title":[{"title_sort":"Rare disease registries are key to evidence-based personalized medicine","title":"Rare disease registries are key to evidence-based personalized medicine","subtitle":"highlighting the european experience"}]} 
SRT |a KOELKERSTERAREDISEAS0420